- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02347605
Medicinal Nicotine for Preventing Cue Induced Craving
December 15, 2017 updated by: University of Minnesota
The purpose of this study is to determine if changing the timeframe (relative to cue presentation) at which the nicotine lozenge is given can attenuate the increase in symptoms of tobacco craving and withdrawal that occur when smokers are presented with smoking cues.
In this cross-over study, all subjects attend three laboratory sessions at which either nicotine lozenge or placebo is given prior to presentation of smoking cues or after presentation of smoking cues.
The order in which the three conditions will be presented are randomized.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Clinical and Translational Sciences Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Smoking a minimum number of cigarettes per day
- General good health
Exclusion Criteria:
- unstable medical or psychiatric conditions
- history of severe motion sickness (due to virtual reality equipment used to present cues)
- women who are pregnant or breast feeding
The investigators will evaluate if there are other reasons why someone may not participate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nicotine lozenge 4 mg prior to cue exposure
Nicotine lozenge is used 15 minutes prior to smoking cue exposure
|
|
Placebo Comparator: Placebo lozenge prior to cue exposure
Placebo lozenge is used 15 minutes prior to smoking cue exposure
|
|
Other: Control condition: Lozenge after cue exposure
Lozenge is used immediately after smoking cue exposure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Craving Symptom Severity Score Assessed Via Questionnaire
Time Frame: approximately 15 minutes
|
Craving as assessed via the craving question on the Minnesota Nicotine Withdrawal Scale.
The score range is from 0 (no craving) to 4 (severe craving).
The outcome measure is the change in craving score from before cue exposure to craving score after cue exposure.
|
approximately 15 minutes
|
Withdrawal Symptom Severity Score Assessed Via Questionnaire
Time Frame: approximately 15 minutes
|
Withdrawal as assessed via the Minnesota Nicotine Withdrawal Scale.
The score range is from 0 to 28 with higher scores indicating more severe withdrawal symptoms.
The outcome measure is the change in withdrawal score from before cue exposure to the withdrawal score after cue exposure.
|
approximately 15 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Michael Kotlyar, PharmD, University of Minnesota
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2013
Primary Completion (Actual)
January 1, 2015
Study Completion (Actual)
January 1, 2015
Study Registration Dates
First Submitted
January 14, 2015
First Submitted That Met QC Criteria
January 21, 2015
First Posted (Estimate)
January 27, 2015
Study Record Updates
Last Update Posted (Actual)
December 18, 2017
Last Update Submitted That Met QC Criteria
December 15, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
- WS2385492
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use Disorder
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
Harvard School of Public Health (HSPH)Beacon Communities; The Community BuildersEnrolling by invitationTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Second Hand Tobacco SmokeUnited States
-
University of California, San FranciscoNational Institute on Minority Health and Health Disparities (NIMHD)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of California, San FranciscoTobacco Related Disease Research ProgramCompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Smoking, Tobacco | Smoking, CigaretteUnited States
-
New York State Psychiatric InstituteTerminatedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Nicotine Dependence | Cigarette Smoking | Tobacco Dependence | Nicotine Use Disorder | Smoking, CigaretteUnited States
-
Rutgers, The State University of New JerseyNational Institute on Drug Abuse (NIDA)CompletedSchizophrenia | Schizoaffective Disorder | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use CessationUnited States
-
University of PennsylvaniaFood and Drug Administration (FDA)Completed
-
University of Kansas Medical CenterCompletedTobacco Use Disorder/Cigarette SmokingUnited States
-
Ottawa Hospital Research InstituteCompletedTobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence
Clinical Trials on Nicotine lozenge 4 mg
-
GlaxoSmithKlineCompletedHealthy Volunteer Smokers
-
McNeil ABCompletedTobacco DependenceRussian Federation
-
McNeil ABCompletedTobacco DependenceSweden
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
McNeil ABCompletedSmoking CessationSweden
-
McNeil ABCompletedTobacco DependenceSweden
-
University of VirginiaNot yet recruiting
-
RAI Services CompanyNot yet recruiting
-
McNeil ABCompletedTobacco DependenceSweden
-
US Department of Veterans AffairsTerminated